Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. - Wikidata - awgldk - TriplyDB

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.

http://www.wikidata.org/entity/Q46818617

about

Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for development of type 2 diabetes mellitus New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects Urine-derived induced pluripotent stem cells as a modeling tool to study rare human diseases Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease Influence of Familial Renal Glycosuria Due to Mutations in the SLC5A2 Gene on Changes in Glucose Tolerance over Time Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models The renal dopaminergic system: novel diagnostic and therapeutic approaches in hypertension and kidney disease.Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes A linear relationship between the ex-vivo sodium mediated expression of two sodium regulatory pathways as a surrogate marker of salt sensitivity of blood pressure in exfoliated human renal proximal tubule cells: the virtual renal biopsy.Diagnostic tools for hypertension and salt sensitivity testing.Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Generation of induced pluripotent stem cells from urine.The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.Isolation and characterization of a primary proximal tubular epithelial cell model from human kidney by CD10/CD13 double labeling Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Evaluation of Digital PCR as a Technique for Monitoring Acute Rejection in Kidney Transplantation The HMGA1-IGF-I/IGFBP system: a novel pathway for modulating glucose uptake.Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects.Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.A fluorescence method for measurement of glucose transport in kidney cells Current therapies and emerging drugs in the pipeline for type 2 diabetes.Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetes Generation of human induced pluripotent stem cells from urine samples.The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.The Sweet Pee model for Sglt2 mutation Empagliflozin in the treatment of type 2 diabetes: evidence to date

P2860

Q24185874-9F4FAF02-8427-429E-8924-76B728984B10 Q24186087-06CA9AE3-55D5-4F78-AE25-9DE56B56ACCA Q26739475-7FE97927-084E-4F66-8F69-531C03A90600 Q26767263-C5930A3A-ED74-4703-8A30-0B061417BBCC Q26782225-EDC46F1C-E5CE-47EF-AB8D-D1B80CC18CE5 Q26864336-6C73BDCF-A0EF-40DA-9ECA-DE693306692B Q27010669-BC188CCF-5A30-4AE7-B1AF-128FDA69C5D0 Q27027105-87262133-D018-4503-BC82-11D165F3A1E3 Q28072765-F4F1D97A-5408-4AA0-A1AC-2B6F9F229F38 Q28073204-A653D132-C1ED-4894-ACAC-AC7012CAC949 Q28074843-ADE9BFDA-118B-4F63-9DE3-F0C18B071F5B Q28080114-E6FB4AE7-1AEF-48A6-87C1-4E0CDA88E993 Q28477142-CD6FC577-5DC9-4A0C-A7A0-84DF67E6A6BD Q28552106-EDCEE028-5C74-4F96-B706-7097E6763AE9 Q28732080-EF9D977B-687E-4EDD-851E-3A6A0A282DF6 Q30360038-506A9ABA-4163-4984-BF29-A0FB945F8803 Q30377441-9B96B764-B37F-4973-9CAF-284B449E046D Q30412608-6AF5C142-D680-4992-AAB4-7D31A5249A5E Q30417367-29E175D8-D9F5-421B-9B41-4A8DB6CED675 Q30426407-C9168B46-D88B-4677-9CA2-ED03C96D869F Q30502509-9622D283-E6E5-4F1C-AABF-AACEADF6449B Q30663494-FCC2840E-56F3-499C-9AD0-A8DCCF607B6F Q31121258-0CACAFFF-757D-4CA5-A8D8-D7925971BF15 Q32186373-10F29D41-D7E0-4BA9-9945-1830A951F184 Q33559093-3E0C6BA1-C747-4F4B-B50A-DDF68F1AB913 Q33636295-C0F125C9-6912-496B-89E3-56A8CF2C6A14 Q33771405-E904223A-1734-431C-8E51-A11B55D34642 Q33837017-8A6AAC17-9886-4467-B9F2-5167ECB12D5E Q33871397-BE38E95C-E1F8-4D5A-8D88-8FAC2221005B Q33878898-E78D7F05-48C3-4FCC-A07B-83655D2B1008 Q33928941-918BA837-9B79-4402-9AE0-F18DCE3B1FF1 Q34105064-F39B7A85-FF63-4462-A027-414F8238167E Q34120717-9C81B8AE-54B6-46DF-AB5C-67606336BB28 Q34153496-924F00E6-2055-4D42-BA1F-18688E3BDAB0 Q34161881-9345B7C9-3297-4ECB-9604-243D78B7AC84 Q34198692-F07B9AB4-16DE-4AD6-B697-956BFCC5396E Q34310664-70B22DD5-1D7B-43E7-98EA-0AAFD2DD66B9 Q34315521-47A59FED-3917-4DC9-8D95-EC6339AC0194 Q34457273-00F2A063-FA32-45A4-8FC6-8406DB2FE992 Q34502358-A95DB4DC-734A-45CE-96E1-A71A58A9B9E1

P2860

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.

http://www.wikidata.org/entity/Q46818617

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Glucose transporters in human ...... on-insulin-dependent diabetes.

@en

Glucose transporters in human ...... on-insulin-dependent diabetes.

@nl

type

label

Glucose transporters in human ...... on-insulin-dependent diabetes.

@en

Glucose transporters in human ...... on-insulin-dependent diabetes.

@nl

prefLabel

Glucose transporters in human ...... on-insulin-dependent diabetes.

@en

Glucose transporters in human ...... on-insulin-dependent diabetes.

@nl

P1433

Q46818617-C6B5320B-8A6B-4F07-99AA-469B979F4CD6

P1476

Q46818617-FF32E6FF-5809-4D41-901E-C3292590B07D

P2093

Q46818617-015A9CF1-D523-47C2-A3F5-BA381B972A31

Q46818617-33B8AC16-8B2F-4B37-BBDD-4AF62E55C0D5

Q46818617-40E0F148-D03E-46C9-BFFE-84BBF5BBCDE1

Q46818617-6539922A-FAF6-4917-B62E-8ECFFD10B73C

Q46818617-76EF65DC-0D44-4E03-BE99-2B66AC85058F

Q46818617-C4375F16-CE61-42C2-834D-E04A722F0CE3

P304

Q46818617-4932F9EA-A42D-438D-8398-16E00D523D55

P31

Q46818617-A067D356-EB48-4A42-8970-0DDBB56CAE14

P356

Q46818617-04AF1A76-EDEE-4DA5-B9BC-5E12D42F0111

P407

Q46818617-DD3649D4-EE89-4460-BE74-B54A8DEB17D0

P433

Q46818617-B64866E8-DD4A-4A1B-88A8-798239BCEF1C

P478

Q46818617-F1A9D66C-B6CC-490B-85B5-6A296E0A6F1F

P577

Q46818617-EE09B207-AA4C-4285-A783-8FA19489E9C3

P5875

Q46818617-4ED3321D-EDF2-47FE-8651-91B56D2F2907

P698

Q46818617-3673D46E-B25E-42C1-A4A6-23E7F6C8AAF8

P921

Q46818617-26a69bb9-5a64-4317-be74-b3bc737755b3

Q46818617-2B6BB2FF-5116-4446-86BA-3571C086F1F9

Q46818617-E60E78AC-A7F8-4A43-A209-51F9394A3610

P356

DIABETES.54.12.3427

P1433

P1476

Glucose transporters in human ...... on-insulin-dependent diabetes.

@en

P2093

Chari D Smith

http://www.w3.org/2001/XMLSchema#string

Guizhu Hong

http://www.w3.org/2001/XMLSchema#string

Hassan Rahmoune

http://www.w3.org/2001/XMLSchema#string

Joanna M Ward

http://www.w3.org/2001/XMLSchema#string

John Brown

http://www.w3.org/2001/XMLSchema#string

Paul W Thompson

http://www.w3.org/2001/XMLSchema#string

P304

3427-3434

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DIABETES.54.12.3427

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7463181

http://www.w3.org/2001/XMLSchema#string

P698

16306358

http://www.w3.org/2001/XMLSchema#string

P921